Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,003 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib.
Parekh V, Sobanko J, Miller CJ, Karakousis G, Xu W, Letrero R, Elenitsas R, Xu X, Elder DE, Amaravadi R, Schuchter LM, Nathanson KL, Wilson MA, Chu EY. Parekh V, et al. Among authors: wilson ma. J Cutan Pathol. 2019 Mar;46(3):190-194. doi: 10.1111/cup.13401. Epub 2018 Dec 27. J Cutan Pathol. 2019. PMID: 30552700 Free PMC article.
Molecular testing in melanoma.
Wilson MA, Nathanson KL. Wilson MA, et al. Cancer J. 2012 Mar-Apr;18(2):117-23. doi: 10.1097/PPO.0b013e31824f11bf. Cancer J. 2012. PMID: 22453011 Free PMC article. Review.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, DeMarini DJ, Gilmer TM, Martin AM, Marmorstein R, Schultz DC, Speicher DW, Karakousis GC, Xu W, Amaravadi RK, Xu X, Schuchter LM, Herlyn M, Nathanson KL. Villanueva J, et al. Cell Rep. 2013 Sep 26;4(6):1090-9. doi: 10.1016/j.celrep.2013.08.023. Epub 2013 Sep 19. Cell Rep. 2013. PMID: 24055054 Free PMC article.
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603.
Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty KT, Lee SJ, Wilson MA, Nathanson KL, Benos PV, Tawbi HA. Villaruz LC, et al. Among authors: wilson ma. Clin Epigenetics. 2015 Jun 4;7(1):58. doi: 10.1186/s13148-015-0092-2. eCollection 2015. Clin Epigenetics. 2015. PMID: 26052356 Free PMC article.
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Wilson MA, et al. Clin Cancer Res. 2016 Jan 15;22(2):374-82. doi: 10.1158/1078-0432.CCR-15-1162. Epub 2015 Aug 25. Clin Cancer Res. 2016. PMID: 26307133 Free PMC article. Clinical Trial.
Chemotherapy for Melanoma.
Wilson MA, Schuchter LM. Wilson MA, et al. Cancer Treat Res. 2016;167:209-29. doi: 10.1007/978-3-319-22539-5_8. Cancer Treat Res. 2016. PMID: 26601864 Review.
1,003 results